Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06804655 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacoscopy for Patients With Refractory Primary Brain Tumors

Study acronym: EViDENCE-BT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Jun 1, 2026 to Sep 11, 2026 · Eligibility criteria expanded, about 17 words · Site details revised at 3 of 3 sites · 1 more Show 4 more changesShow less
    • Start date changed from estimate of Jun 1, 2026 to Sep 11, 2026
    • Eligibility criteria expanded, about 17 words
    • Site details revised at 3 of 3 sites
    • Publications: details revised at 1 of 1 entry
  2. Start date: Feb 12, 2026 to Jun 1, 2026v4
  3. Start date: Sep 12, 2025 to Feb 12, 2026 Trial status: Recruiting to Not Yet Recruiting · Site details revised at 3 of 3 sitesv3 Show 2 more changesShow less
    • Trial status: Recruiting to Not Yet Recruiting
    • Site details revised at 3 of 3 sites
  4. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jan 15, 2026 to Sep 15, 2028 · Start date changed from estimate of Apr 1, 2025 to Sep 12, 2025 · Completion date: Aug 15, 2026 to Sep 15, 2028 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Jan 15, 2026 to Sep 15, 2028
    • Start date changed from estimate of Apr 1, 2025 to Sep 12, 2025
    • Completion date: Aug 15, 2026 to Sep 15, 2028
    • Site details revised at 3 of 3 sites
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Zurich
157 trials monitored
See 3 trials at risk
Glioblastoma
670 trials monitored
See 44 trials at risk
Glioma
668 trials monitored
See 40 trials at risk
Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level. This personalized therapeutic approach was developed and validated in pre-clinical glioma models. With the current research proposal, we seek to establish feasibility for a clinical interventional trial for patients with refractory primary brain tumors that is based on pharmacoscopy-guided selection of treatment. The study is supported by an unrestricted grant from Anti Cancer Fund.
Trial Details
NCT Number NCT06804655
Lead Sponsor University of Zurich
Collaborators: University Hospital, Zürich, University Hospital, Basel, Switzerland, Cantonal Hospital of St. Gallen
Conditions Brain (Nervous System) Cancers, Glioblastoma, Glioma, Ependymoma, Medulloblastoma, Meningioma, Rare Primary Brain Tumors, Rare CNS Primary Tumors
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov